Diabetes In Control While 24.5% patients on metformin required an add-on oral medication , 37.1% of patients on sulfonylurea, 39.6% of patients on thiazolidinedione , and 36.2% patients on DPP-4 inhibitor required an add-on oral medication . Moreover, 5.1% of patients on ...
Medscape In addition to the major risk factors for osteoporotic fracture, low bone mineral density (BMD), age, low body weight and history of fracture or falls, some drugs are now considered to be important secondary risk factor for bone loss and fracture ... and more »
Diabetes News Journal In this study, the authors performed a retrospective analysis and determined how the use of thiazolidinediones (TZDs, a class of drugs used in the treatment of diabetes mellitus type 2) impacts the necessity for re-intervention in diabetic patients ...
HealthDay The researchers found that around 40 percent of people taking a sulfonylurea, a thiazolidinedione , or a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor) ad...
NICE It is an oral, once-daily medication belonging to a class of drugs called sodium glucose co-transporter (SGLT-2) inhibitors. The draft guidance is now with cons...
Clinical Advisor Clinical trials: Tanzeum was studied as monotherapy and in combination with metformin, metformin + sulfonylurea, thiazolidinedione ± metformin, and insulin glargine ± oral antidiabetics. The efficacy of Tanzeum was compared with placebo, glimepiride, ...
